Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Double-blind Comparative Study of TAK-875

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: TAK-875
Drug: Placebo

First Posted Date: 2011-09-14

Last Posted Date: 2012-11-09

Lead Sponsor: Takeda

Target Recruit Count: 192

Registration Number: NCT01433393

Long-term Study of SYR-472

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: SYR-472

First Posted Date: 2011-09-12

Last Posted Date: 2023-12-14

Lead Sponsor: Takeda

Target Recruit Count: 680

Registration Number: NCT01431807

A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain

Phase 3

Completed

Conditions: Break Through Pain
Cancer

Interventions: Drug: Intranasal Fentanyl Spray (INFS)
Drug: Placebo

First Posted Date: 2011-09-05

Last Posted Date: 2014-03-26

Lead Sponsor: Takeda

Target Recruit Count: 46

Registration Number: NCT01429051

This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiology Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Korea

Completed

Conditions: COPD

First Posted Date: 2011-08-18

Last Posted Date: 2013-04-18

Lead Sponsor: Takeda

Target Recruit Count: 1118

Registration Number: NCT01419379

Locations: 🇰🇷
Nycomed Investigational Site, Ulsan, Korea, Republic of

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: TAK-875 and Sitagliptin
Drug: Placebo
Drug: TAK-875
Drug: Sitagliptin

First Posted Date: 2011-08-11

Last Posted Date: 2016-04-04

Lead Sponsor: Takeda

Target Recruit Count: 368

Registration Number: NCT01414920

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Lu AA21004

First Posted Date: 2011-07-15

Last Posted Date: 2013-11-05

Lead Sponsor: Takeda

Target Recruit Count: 119

Registration Number: NCT01395147

Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants

Phase 1

Completed

Conditions: Pharmacokinetics and Pharmacodynamics

Interventions: Drug: Alogliptin

First Posted Date: 2011-07-12

Last Posted Date: 2013-03-22

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT01391663

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Veltuzumab

First Posted Date: 2011-07-11

Last Posted Date: 2016-04-13

Lead Sponsor: Takeda

Target Recruit Count: 300

Registration Number: NCT01390545

Locations: 🇬🇧
Nycomed Investigational Site, Barnsley, S. Yorkshire, United Kingdom

Study of TAK-816 in Healthy Infants

Phase 3

Completed

Conditions: Immunization

Interventions: Biological: ActHIB+ DPT-TAKEDA
Biological: TAK-816+ DPT-TAKEDA

First Posted Date: 2011-06-23

Last Posted Date: 2013-03-05

Lead Sponsor: Takeda

Target Recruit Count: 416

Registration Number: NCT01379846

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Phase 3

Completed

Conditions: Treatment Outcome

Interventions: Drug: Escitalopram
Drug: Vortioxetine
Drug: Placebo

First Posted Date: 2011-06-02

Last Posted Date: 2014-10-09

Lead Sponsor: Takeda

Target Recruit Count: 447

Registration Number: NCT01364649

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy